Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

Figures & data

Table 1 Reported global annual product sales by calendar year for selected medicines according to company annual reports (2004–2017) (in million USD)^a

Table 2 Key dates and relevant protection periods for sofosbuvir, imatinib, and trastuzumab, based on SPCs granted in France [56, 64, 71]

Table 3 SPCs status of TDF/FTC and access to PrEP

Gilead. Fourth quarter and full year financial results 2004–2017. Available from: https://www.gilead.com/news/press-releases/. Accessed 11 Dec 2019.

 Google Scholar

Roche. Financial reports 2004–2017. Available from: https://www.roche.com/investors/downloads.htm. Accessed 11 Dec 2019.

 Google Scholar

Novartis. Annual reports 2004–2017. Available from: https://www.novartis.com/investors/novartis-annual-reporting-suite/annual-report-and-20-f-archive#ui-id-3=1. Accessed 11 Dec 2019.

 Google Scholar

National Industrial Property Institute of France, Supplementary Protection Certificate FR14C0082. https://bases-brevets.inpi.fr/en/document-en/FR14C0082.html?p=5&s=1576078625187&cHash=1775515fafe3642917f44bedbd6dc29e. Accessed 11 Dec 2019.

 Google Scholar

National Industrial Property Institute of France, Supplementary Protection Certificate FR02C0012 (Novartis. Imatinib mesilate). France. 2014. https://bases-brevets.inpi.fr/en/document-en/FR02C0012.html?p=5&s=1576080671877&cHash=9608a45d568e01d4bbcefd69ae640561. Accessed 11 Dec 2019.

 Google Scholar

The National Industrial Property of France (INPI), CCP de médicament (SPC), FR04C0007 (Genentech, Humanized heregulin antibody). Paris. 2010. https://bases-brevets.inpi.fr/en/document-en/FR04C0007.html. Accessed 11 Dec 2019.

 Google Scholar

Medicijnkosten. Zorgintituut Nederland. Available from: https://www.medicijnkosten.nl.

 Google Scholar

Vergoedbare geneesmiddelen. Riziv. Available from: http://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/nl/Public/ProductSearch.

 Google Scholar

British National Formulary. Medicines Complete, The Royal Pharmaceutical Society. Available from: https://about.medicinescomplete.com/#/content/bnf/_180330626?hspl=truvada#DMD9098011000001105.

 Google Scholar

Danish Medicines Agency. Database Medicinpriser.dk. Available from: https://medicinpriser.dk/default.aspx.

 Google Scholar

Legemiddelsøk. Norwegian Medicines Agency. Available from: https://www.legemiddelsok.no.

 Google Scholar

Fiche de presentation Truvada. Ministère des Affaires Sociales et de la Santé. Available from: http://medicprix.sante.gouv.fr/medicprix/detailPresentation.do?parameter=afficherPresDetail&idPresentation=49800.

 Google Scholar

ABDATA: Pharma-Daten-Service. Mediengruppe Deutscher Apotheker. Available from: http://abdata.de/datenangebot/abda-datenbank/.

 Google Scholar

Arzneimitteldatenbank. Arznei-telegramm®. Available from: https://www.arznei-telegramm.de/01atd_info1.php3.

 Google Scholar

Medikamentensuche. Mymedi.ch. Available from: https://www.mymedi.ch/.

 Google Scholar

IPU product file. Irish Pharmacy Union. Dublin. Available from: https://ipu.ie/home/ipu-product-file/.

 Google Scholar

Pharmaceutisch Weekblad. PrEP verkrijgbaar voor € 50 per maand. Den Haag: PW04; 2018.

 Google Scholar

Teva and others vs. Gilead. [2017] EWHC 13 (Pat): England and Wales High Court (Patent Court); 2017.

 Google Scholar

Wilson C. Massive drop in London HIV rates may be due to internet drugs. London: New Scientist; 2018.

 Google Scholar

The SPC Blog. Denmark – Gilead successfully enforces its SPC for Truvada. 2018. Available from: http://thespcblog.blogspot.com/2018/03/denmark-gilead-successfully-enforces.html. Accessed 11 Dec 2019.

 Google Scholar

La PrEP: AIDES; 2018. Available from: https://www.aides.org/prep. Accessed 11 Dec 2019.

 Google Scholar

PrEP will soon be available for 50 Euros in Germany, starting in seven cities Berlin: Deutsche Aidshilfe; 2017. Available from: https://www.aidshilfe.de/meldung/prep-will-soon-available-50-euros-germany-starting-seven-cities. Accessed 11 Dec 2019.

 Google Scholar

Halpin H. A HIV prevention drug is being made available to Irish pharmacies at a 70% cheaper cost. Dublin: TheJournal.ie; 2017.

 Google Scholar

Hiv-preventiepil PrEP na jarenlange lobby in Nederland vergoed, Aidsfonds mist urgentie bij minister Amsterdam: AT5; 10 juli 2018. Available from: http://www.at5.nl/artikelen/184165/hiv-preventiepil-prep-na-jarenlange-lobby-in-nederland-vergoed-aidsfonds-mist-urgentie-bij-minister. Accessed 11 Dec 2019.

 Google Scholar

Geneesmiddel in PrEp om een HIV-infectie te voorkomen: terugbetaling vanaf 1 juni 2017: Riziv; 2017. Available from: http://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/terugbetalen/specialiteiten/wijzigingen/Paginas/geneesmiddelen-PrEp-HIV.aspx#.W0jMyGePXXo. Accessed 11 Dec 2019.

 Google Scholar

PrEP on the NHS London: I want PrEP now. Available from: https://www.iwantprepnow.co.uk/prep-on-the-nhs. Accessed 11 Dec 2019.

 Google Scholar

Collis H. England’s HIV prevention trial to test generic Truvada. Brussels: Politico; 2017.

 Google Scholar

Duffy N. Norway to provide free HIV-preventing PrEP drugs to at-risk gay men. London: Pink News; 2016.

 Google Scholar

Schwinn M. HIV-prophylaxe soll krankenkassenleistung werden. Munich: Süddeutsche Zeitung; 2018.

 Google Scholar

PrEP Zürich: Aide Suisse Contre le Sida. Available from: https://www.aids.ch/en/faq/protection-risk/prep.php. Accessed 11 Dec 2019.

 Google Scholar

Finnegan B. More affordable PrEP to be made available in Irish pharmacies. Dublin: GCN; 2017.

 Google Scholar

XE. Available from: www.xe.com.

 Google Scholar

Availability of data and materials

All data generated or analysed during this study are included in this published article.